



## **HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference**

August 28, 2024 at 8:57 AM EDT

NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA", the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York.

Dr. Malte Peters, Hookipa's Chief Executive Officer, and Terry Coelho, Executive Vice President & Chief Financial Officer will be hosting one-on-one meetings with investors during the conference. In addition, Dr. Peters will participate in a Fireside Chat on Monday, September 9, 2024 at 1:30 p.m. ET.

The fireside chat will be available via webcast through the following link: <https://journey.ct.events/view/a5640121-61ef-4c2b-8017-b6b346ca2547>

A replay of this webcast will be available within the Investors & Media section of HOOKIPA's website at <https://ir.hookipapharma.com/events>. Archived replays will be accessible for 90 days following each event.

### **About HOOKIPA**

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA's pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at [www.hookipapharma.com](http://www.hookipapharma.com).

For further information, please contact:

### **Investor Contact**

Chuck Padala  
Managing Director, LifeSci Advisors  
[chuck@lifesciadvisors.com](mailto:chuck@lifesciadvisors.com)